Molecular diagnostics is one of the fastest growing areas of biotechnology product development. Once firmly rooted in the research side of the business, DNA testing is quickly making headway in the clinical arena in, for example, prenatal, tissue typing, and inherited disease applications. However, some industry analysts maintain that concern over reimbursement is acting as a roadblock to an even greater penetration of molecular diagnostic tests in the medical field. Do you agree?
Is insufficient reimbursement holding molecular diagnostic tests back from reaching the clinic?